AcelRx Pharmaceuticals is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Co.'s DSUVIA™ and Zalviso, are both focused on the treatment of acute pain, and each utilize sufentanil, for use in medically supervised settings. DSUVIA is indicated for use in adults in a certified medically supervised healthcare setting, such as hospitals, surgical centers, and emergency departments, for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Zalviso is for the management of moderate-to-severe acute pain in hospitalized adult patients. We show 42 historical shares outstanding datapoints in our coverage of ACRX's shares outstanding history.
Understanding the changing numbers of ACRX shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ACRX versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ACRX by allowing them to research ACRX shares outstanding history
as well as any other stock in our coverage universe. |
Video: Shares Outstanding Importance
